First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Inventprise

Status and phase: Enrolling; Phase 1

Conditions: Diarrhea; Shigella

Treatments: Biological: IVT Shigella-04; Biological: Placebo (0.9% saline)

Study type: Interventional

Funder types: Industry

Identifiers

NCT07205926

IVT 514

Details and patient eligibility

About

Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults

Full description

A phase 1 single-site, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of a 2-dose regimen of IM injection of 5 dose formulations of IVT Shigella-04 vaccine with and without adjuvant among 60 healthy individuals aged 18 to 49 years. Approximately 12 eligible participants will be enrolled in the specified 5 sequential dose cohorts and randomized in a 5:1 ratio to receive 2 IM injections of IVT Shigella-04 or placebo (normal saline) at a 28-day interval.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 49 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Participants who meet all the following criteria may be included in the study:

1. Age 18 to 49 years at the time of Dose 1
2. Good general health status, as determined by medical history, physical examination, safety laboratory tests, ECG, vital signs, and clinical judgment
3. BMI ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2
4. Negative alcohol breath test and urine drug screen results at Screening and on Day 1
5. All women: negative serum pregnancy test at Screening and negative urine pregnancy on Day 1
6. Women of childbearing potential (see definition in Section 6.6.1): willingness to use a highly effective form of contraception (see list in Section 6.6.1) through 28 days after the last IP dose
7. Willingness to attend all protocol visits and to have all protocol-required procedures
8. Provision of written informed consent

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study:

1. Currently lactating
2. History of shigellosis or participation in a Shigella challenge study
3. History of bloody diarrhea without alternative diagnosis
4. History of inflammatory bowel disease
5. History of anaphylaxis or angioedema
6. History of malignancy, excluding nonmelanoma skin cancer, cervical carcinoma in situ, and malignancies considered cured > 5 years prior to Day 1
7. History of diabetes mellitus (Individuals with diet-controlled diabetes or history of gestational diabetes are eligible if screening blood glucose is normal and there has been no requirement for antidiabetic medication in the last year.)
8. Known hypersensitivity to any of the ingredients in IVT Shigella-04
9. Inadequate venous access for repeated phlebotomy
10. Any screening laboratory test result outside the normal range and grade ≥ 2 according to the FDA's toxicity grading scale for vaccine trials in healthy adults and adolescents; (Elevated creatine kinase and isolated elevations of bilirubin may be Grade 2 if hepatic transaminases are normal and the Investigator attributes the abnormality to exercise or Gilbert's syndrome. Potential cases of benign ethnic neutropenia should be discussed with the Medical Monitor)
11. Positive serologic test for human HIV-1 or HIV-2 antibody, hepatitis B surface antigen, or hepatitis C antibody
12. Immunodeficiency or chronic administration (> 14 consecutive days) of immunosuppressant or other immune-modifying drugs (see details in Section 6.6.2), including systemic glucocorticoids, within 6 months before Day 1 (topical, intra-articular, or inhaled glucocorticoids permitted)
13. Previous receipt of a licensed or investigational Shigella vaccine
14. Planned receipt of any other vaccine through Day 57
15. Receipt of blood transfusion or blood product within 6 months before Day 1 or planned receipt through Day 57
16. Receipt of any other IP within 90 days before Day 1 or planned receipt through the end of the study
17. Planned elective hospitalization or surgical procedure through the end of the study
18. Occupational exposure to Shigella (eg, laboratory work)
19. Residence ≥ 6 months in a low-income or lower-middle-income country as defined by the World Bank (https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html)
20. Employee of Inventprise, vendors, or research sites associated with the study
21. Any medical, psychiatric, substance use, or social condition that, in the judgment of the Investigator, may pose a risk to the participant or interfere with protocol adherence, assessment of study objectives, or ability to provide informed consent

Temporary Delay Criteria

Administration of IVT Shigella-04/placebo will be delayed for any participant who meets any of the following criteria:

1. Receipt of any vaccine in the past 7 days
2. Febrile illness (eg, oral temperature ≥ 38.0°C), diarrhea, or other acute illness in the past 48 hours
3. Presence of any other sign, symptom, or medication use that could inhibit the proper vaccine administration of IVT Shigella-04/placebo or interpretation of diary data

These criteria are temporary or self-limiting, and IVT Shigella-04/placebo may be administered once the time frame has elapsed/the condition has resolved.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 6 patient groups, including a placebo group

Shigella-04 Low Dose without adjuvant (0.5 mL dose)

Experimental group

Description:

Subjects will receive a 0.5 mL dose of the Shigella-04 low-dose formulation of each conjugated OPS, and administered via intramuscular injection on Day 1 and 29

Treatment:

Biological: IVT Shigella-04

Shigella-04 Low Dose with adjuvant (0.5 mL dose)

Experimental group

Description:

Subjects will receive a 0.5 mL dose of the Shigella-04 low-dose formulation of each conjugated OPS, with adjuvant, administered via intramuscular injection on Day 1 and 29

Treatment:

Biological: IVT Shigella-04

Shigella-04 Medium Dose without adjuvant (0.5 mL dose)

Experimental group

Description:

Subjects will receive a 0.5 mL dose of the Shigella-04 medium-dose formulation of each conjugated OPS, and administered via intramuscular injection on Day 1 and 29

Treatment:

Biological: IVT Shigella-04

Shigella-04 Medium Dose with adjuvant (0.5 mL dose)

Experimental group

Description:

Subjects will receive a 0.5 mL dose of the Shigella-04 medium-dose formulation of each conjugated OPS, with adjuvant, administered via intramuscular injection on Day 1 and 29

Treatment:

Biological: IVT Shigella-04

Shigella-04 High Dose without adjuvant (1.0 mL dose)

Experimental group

Description:

Subjects will receive a 1.0 mL dose of the Shigella-04 high-dose formulation of each conjugated OPS, and administered via intramuscular injection on Day 1 and 29

Treatment:

Biological: IVT Shigella-04

Placebo - 0.9% Saline

Placebo Comparator group

Description:

0.9% saline

Treatment:

Biological: Placebo (0.9% saline)